Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)

Oncotarget

Volumn 7, Issue 6, 2016, Pages 6984-6993

  Lee, Ji Yun ^a   Qing, Xu ^b   Xiumin, Wei ^b   Yali, Bai ^b   Chi, Sangah ^a   Bak, So Hyeon ^c   Lee, Ho Yun ^a   Sun, Jong Mu ^a   Lee, Se Hoon ^a   Ahn, Jin Seok ^a   Cho, Eun Kyung ^d   Kim, Dong Wan ^e   Kim, Hye Ryun ^f   Min, Young Joo ^g   Jung, Sin Ho ^a   Park, Keunchil ^a   Mao, Mao ^b   Ahn, Myung Ju ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b WUXI APPTEC   (China)

^c Kangwon National University   (South Korea)

^d Gachon University College of Medicine   (South Korea)

^e Seoul National University Hospital   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

^g University of Ulsan College of Medicine   (South Korea)

Author keywords

Droplet digital PCR; EGFR; Liquid biopsy; NSCLC; TKI treatment

Indexed keywords

CELL DNA; CELL FREE DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DROPLET DIGITAL POLYMERASE CHAIN REACTION; DRUG BLOOD LEVEL; EGFR GENE; FEMALE; GENE MUTATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; ADENOCARCINOMA; BLOOD; CANCER GRADING; CANCER STAGING; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; FOLLOW UP; GENE EXPRESSION PROFILING; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SOUTH KOREA; SURVIVAL RATE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; LONGITUDINAL STUDIES; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPUBLIC OF KOREA; SURVIVAL RATE;

EID: 84963498686     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6874     Document Type: Article

References (41)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
2. Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Park EC and Lee JS. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat. 2011; 43:1-11.
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350:2129-2139.
4. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304:1497-1500.
5. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361:947-957.
6. Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, Lee JS, Yoon SJ, Han JH, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012; 30:1122-1128.
7. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12:735-742.
8. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15:213-222.
9. Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, Tada H, Kuwano H and Mitsudomi T. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res. 2006; 12:5764-5769.
10. Ohashi K, Maruvka YE, Michor F and Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol. 2013; 31:1070-1080.
11. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG and Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005; 2:e73.
12. Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA and Pao W. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. 2006; 12:6494-6501.
13. Weber B, Meldgaard P, Hager H, Wu L, Wei W, Tsai J, Khalil A, Nexo E and Sorensen BS. Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays. BMC Cancer. 2014; 14:294.
14. Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, Roz E, Cirenei N, Bellomi M, Pelosi G, Pierotti MA and Pastorino U. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol. 2003; 21:3902-3908.
15. Bremnes RM, Sirera R and Camps C. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer. 2005; 49: 1-12.
16. Kimura H, Suminoe M, Kasahara K, Sone T, Araya T, Tamori S, Koizumi F, Nishio K, Miyamoto K, Fujimura M and Nakao S. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer. 2007; 97:778-784.
17. Yeo CD, Kim JW, Kim KH, Ha JH, Rhee CK, Kim SJ, Kim YK, Park CK, Lee SH, Park MS and Yim HW. Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing. Lung Cancer. 2013; 81:207-212.
18. Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Duan CJ, Wu NM, Guo ZQ, Liu YX, Liu HN, Wang YY, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol. 2009; 27:2653-2659.
19. Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, Makarewicz AJ, Bright IJ, Lucero MY, Hiddessen AL, Legler TC, Kitano TK, Hodel MR, Petersen JF, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem. 2011; 83:8604-8610.
20. Zhang BO, Xu CW, Shao Y, Wang HT, Wu YF, Song YY, Li XB, Zhang Z, Wang WJ, Li LQ and Cai CL. Comparison of droplet digital PCR and conventional quantitative PCR for measuring gene mutation. Exp Ther Med. 2015; 9:1383-1388.
21. Aparicio S and Caldas C. The implications of clonal genome evolution for cancer medicine. N Engl J Med. 2013; 368:842-851.
22. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366:883-892.
23. Diaz LA, Jr. and Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014; 32:579-586.
24. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012; 486:532-536.
25. Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, Zorzi J, Jeter SC, Oliver GR, Fetting J, Emens L, Riley C, Stearns V, et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res. 2012; 18:3462-3469.
26. Diaz LA, Jr., Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS and Vogelstein B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012; 486:537-540.
27. Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ, Yang XN, An SJ, Wang BC, et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2011; 29:3316-3321.
28. Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P, Jackman DM and Janne PA. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 2014; 20:1698-1705.
29. Yung TK, Chan KC, Mok TS, Tong J, To KF and Lo YM. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res. 2009; 15:2076-2084.
30. Sorensen BS, Wu L, Wei W, Tsai J, Weber B, Nexo E and Meldgaard P. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer. 2014; 120:3896-3901.
31. Mok T, Wu YL, Lee JS, Yu CJ, Sriuranpong V, Sandoval-Tan J, Ladrera G, Thongprasert S, Srimuninnimit V, Liao M, Zhu Y, Zhou C, Fuerte F, et al. Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. Clin Cancer Res. 2015; 21:3196-3203.
32. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352:786-792.
33. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS, Marass F, Humphray S, Hadfield J, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013; 497:108-112.
34. Nakamura T, Sueoka-Aragane N, Iwanaga K, Sato A, Komiya K, Kobayashi N, Hayashi S, Hosomi T, Hirai M, Sueoka E and Kimura S. Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA. J Thorac Oncol. 2012; 7:1369-1381.
35. Sakai K, Horiike A, Irwin DL, Kudo K, Fujita Y, Tanimoto A, Sakatani T, Saito R, Kaburaki K, Yanagitani N, Ohyanagi F, Nishio M and Nishio K. Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor. Cancer Sci. 2013; 104:1198-1204.
36. Janne PA, Ramalingam SS, Yang JC-H, Ahn MJ, Kim DW, Kim SW, Planchard D, Ohe Y, Felip E, Watkins C, Cantarini M, Ghiorghiu S and Ranson M. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC). J Clin Oncol. 2014; 32:abstr 8009.
37. Sequist LV, Soria J-C, Gadgeel SM, Wakelee HA, Camidge DR, Varga A, Solomon BJ, Papadimitrakopoulou V, Jaw-Tsai SS, Caunt L, Kaur P, Rolfe L, Allen AR, et al. First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). J Clin Oncol. 2014; 32:abstr 8010.
38. Kim DW, Lee DH, Kang JH, Park K, Han J-Y, Lee J-S, Jang I-J, Kim H-Y, Son J and Kim J-H. Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs). J Clin Oncol. 2014; 32:Suppl; abstr 8011.
39. Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA and Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res. 2011; 17:5530-5537.
40. Nishino M, Jagannathan JP, Krajewski KM, O'Regan K, Hatabu H, Shapiro G and Ramaiya NH. Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol. 2012; 198:737-745.
41. Nishino M, Jackman DM, Hatabu H, Janne PA, Johnson BE and Van den Abbeele AD. Imaging of lung cancer in the era of molecular medicine. Acad Radiol. 2011; 18:424-436.